CAMP — Camp4 Therapeutics Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1736730 ·
Last close
$3.92
Market Cap
$245.99M
52W High
$7.75
52W Low
$2.81
ADV30
302,417
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,779,000 | — | -13,380,000 | -33,530,000 | 93,428,000 | 86,398,000 | 94,121,000 |
| Mar 2026 | 1,294,000 | — | -13,071,000 | -18,331,000 | 105,457,000 | 99,209,000 | 74,555,000 |
| Dec 2025 | 348,000 | — | -12,776,000 | -40,284,000 | 117,808,000 | 109,517,000 | 70,104,000 |
| Sep 2025 | 795,000 | — | -13,157,000 | -15,099,000 | 86,395,000 | 75,255,000 | 27,728,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-26,248,000
Investing CF
$36,000
Financing CF
$76,098,000
CapEx
$-542,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.11
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-310,487,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-52,032,000
Pretax Income TTM
$-86,301,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,216,000
EBITDA
$-50,561,000
Free Cash Flow
$-12,828,000
Enterprise Value
$182,675,104
Total Cash
$86,398,000
Total Debt
$2,372,000
Shares Out
62,753,200
Trailing EPS
$-2.31
Book Value
$-0.01
ROE
-545.9%
ROA
-45.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,498,000 | -52,061,000 | -80,403,000 | 117,808,000 | 70,104,000 | 47,704,000 | -29,553,000 |
| Dec 2024 | 652,000 | -53,088,000 | -51,791,000 | 78,307,000 | 15,163,000 | 63,144,000 | -45,562,000 |
| Dec 2023 | 350,000 | -51,879,000 | -49,291,000 | 54,946,000 | 178,676,000 | -123,730,000 | -44,155,000 |
| Dec 2022 | 0 | -45,001,000 | -44,192,000 | 102,549,000 | 180,080,000 | -77,531,000 | -38,543,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-13,484,000
OpCashFlow TTM
$0
Assets (Latest)
$78,307,000
Forward EPS
$-0.79
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SIGA | SIGA TECHNOLOGIES INC | $247.88M | $3.45 | — |
| AKBA | Akebia Therapeutics, Inc. | $248.29M | $0.90 | — |
| ACIU | AC Immune SA | $250.56M | $2.52 | — |
| LYEL | Lyell Immunopharma, Inc. | $241.38M | $9.85 | — |
| PRLD | Prelude Therapeutics Inc | $252.17M | $3.88 | — |
News headlines (Yahoo Finance, 1h cache)
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
2026-09-10 11:33 · Yahoo
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
2026-09-08 20:05 · Yahoo
CAMP4 to Participate in Upcoming Investor Conferences
2026-09-01 20:05 · Yahoo
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-08-13 20:05 · Yahoo
Is CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Undervalued Ahead of Key CMP-002 Clinical Development Milestones?
2026-07-02 20:06 · Yahoo
Here's Why We're Not Too Worried About Camp4 Therapeutics' (NASDAQ:CAMP) Cash Burn Situation
2026-06-06 12:57 · Yahoo
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
2026-05-14 11:00 · Yahoo
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-07 20:05 · Yahoo
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 23:05 · Yahoo
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
2026-04-28 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.